Psoriatic skin lesions contain biologically active amounts of an interleukin 1-like compound.

Camp, R.D.R.; Fincham, N.J.; Cunningham, Fiona; Greaves, M.W.; Morris, Jonathan C.; Chu, Alvina

doi:10.4049/jimmunol.137.11.3469

Cited by 74 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Interleukin 1a, Tumor Necrosis Factor a, and Interferon ? in Psoriasis

Gomi¹,

Shiohara²,

Munakata³

et al. 1991

Arch Dermatol

View full text Add to dashboard Cite

Although recent studies have suggested that a variety of cytokines released by keratinocytes and inflammatory leukocytes could contribute to induction or persistence of the inflammatory processes in psoriasis, it remains unclear how production of these cytokines is regulated in psoriatic patients. To elucidate the biologic relevance of these cytokines to the pathogenesis of psoriasis, we investigated serum levels of interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in 21 patients with psoriasis vulgaris, together with 21 healthy controls. The mean serum levels of interleukin 1 alpha and tumor necrosis factor alpha were not significantly different from those in controls, while those of interferon gamma were significantly elevated in the patients with psoriasis. Serum levels of interleukin 1 alpha correlated negatively with clinical disease severity expressed as psoriasis area and severity index score and with duration of psoriasis. In contrast, interferon gamma levels were related, although not significantly, to disease severity. In addition, an inverse correlation was noted between the interleukin 1 alpha levels and interferon gamma levels. These results indicate that interleukin 1 alpha and interferon gamma may be relevant to the induction and perpetuation, respectively, of the inflammatory responses in psoriasis, and that these cytokines, which have similar biologic properties, may strictly regulate one another's production in vivo.

show abstract

Interleukin 1a, Tumor Necrosis Factor a, and Interferon ? in Psoriasis

Gomi¹,

Shiohara²,

Munakata³

et al. 1991

Arch Dermatol

View full text Add to dashboard Cite

show abstract

Quantification of Chemotactic Peptides (C5a Anaphylatoxin and IL-8) in Psoriatic Lesional Skin

Takematsu

Tagami²

1993

Arch Dermatol

View full text Add to dashboard Cite

Based on these results, we speculate that, although IL-8 may exert a synergistic effect with C5a/C5a des Arg in the induction of transepidermal leukocyte chemotaxis, it constitutes a proinflammatory cytokine that is involved in the production of the persistent inflammatory changes characterized by a T-lymphocyte infiltration. In contrast, C5a/C5a des Arg seems to be generated only in the inflammatory lesional skin under specific circumstances that preferentially favor complement activation and also seems to play a major role in the induction of cyclic transepidermal leukocyte chemotaxis from "squirting papillae."

show abstract

Cyclosporine Improves Psoriasis in a Double-blind Study

Ellis¹

1986

JAMA

453

126

View full text Add to dashboard Cite

In a double-blind trial, 21 patients with severe plaque psoriasis were randomly assigned to receive oral cyclosporine, 14 mg/kg/d, or its vehicle. After four weeks of therapy the 11 cyclosporine recipients had the following response to treatment: two had total clearing and six improved markedly, two moderately, and one minimally; whereas ten vehicle-treated patients showed no change or minimal improvement. Vehicle-treated patients, after a switch to cyclosporine for four weeks, demonstrated impressive improvement similar to that seen in patients who initially received only cyclosporine. Moderate or marked improvement or total clearing was noted in 17 (81%) of 21 and 20 (95%) of 21 after one and four weeks of therapy, respectively. Mitotic figures and leukotriene B4 levels in lesions decreased 86% and 64%, respectively, after seven days of cyclosporine therapy. Mononuclear (including activated T cells) and polymorphonuclear leukocyte infiltrates were markedly reduced in lesions of all patients after seven days of cyclosporine therapy. These results suggest that psoriasis may have an immunologic basis mediated by activated T cells and/or other immune cells; if a long-term regimen with a favorable efficacy-side effect ratio can be determined, cyclosporine would be a significant advance in the treatment of psoriasis.

show abstract

Psoriatic skin lesions contain biologically active amounts of an interleukin 1-like compound.

Cited by 74 publications

References 0 publications

Interleukin 1a, Tumor Necrosis Factor a, and Interferon ? in Psoriasis

Interleukin 1a, Tumor Necrosis Factor a, and Interferon ? in Psoriasis

Quantification of Chemotactic Peptides (C5a Anaphylatoxin and IL-8) in Psoriatic Lesional Skin

Cyclosporine Improves Psoriasis in a Double-blind Study

Contact Info

Product

Resources

About